FOCALIN XR Drug Patent Profile

Which patents cover Focalin Xr, and what generic alternatives are available?

Focalin Xr is a drug marketed by Sandoz and is included in one NDA.

The generic ingredient in FOCALIN XR is dexmethylphenidate hydrochloride. There are six drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the dexmethylphenidate hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Focalin Xr

A generic version of FOCALIN XR was approved as dexmethylphenidate hydrochloride by MEDICAP LABS on November 18^th, 2013.

Summary for FOCALIN XR

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FOCALIN XR

Paragraph IV (Patent) Challenges for FOCALIN XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FOCALIN XR	Extended-release Capsules	dexmethylphenidate hydrochloride	25 mg	021802	1	2011-09-30
FOCALIN XR	Extended-release Capsules	dexmethylphenidate hydrochloride	35 mg	021802	1	2011-09-29
FOCALIN XR	Extended-release Capsules	dexmethylphenidate hydrochloride	40 mg	021802	1	2010-12-20
FOCALIN XR	Extended-release Capsules	dexmethylphenidate hydrochloride	30 mg	021802	1	2010-12-15
FOCALIN XR	Extended-release Capsules	dexmethylphenidate hydrochloride	15 mg	021802	1	2007-05-14
FOCALIN XR	Extended-release Capsules	dexmethylphenidate hydrochloride	5 mg, 10 mg and 20 mg	021802	1	2007-03-30

US Patents and Regulatory Information for FOCALIN XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-001	May 26, 2005	AB	RX	Yes	No
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-007	Apr 21, 2011	AB	RX	Yes	No
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-003	May 26, 2005	AB	RX	Yes	No
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-006	Aug 11, 2010	AB	RX	Yes	Yes
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-002	May 26, 2005	AB	RX	Yes	No
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-004	Aug 1, 2006	AB	RX	Yes	No
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-005	Oct 23, 2009	AB	RX	Yes	No

International Patents for FOCALIN XR

See the table below for patents covering FOCALIN XR around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2612994
Hong Kong	1117060
World Intellectual Property Organization (WIPO)	03005962
China	101879140
Brazil	PI0609982
Mexico	2007007942	COMPOSICIONES DE MATERIAL NANOPARTICULADO Y DE LIBERACION CONTROLADA QUE COMPRENDEN UNA CEFALOSPORINA. (NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN.)
Canada	2468370	ADMINISTRATION CHRONIQUE D'UN BOL DE D-THREO METHYLPHENIDATE (CHRONIC, BOLUS ADMINISTRATION OF D-THREO METHYLPHENIDATE)

Investment Scenario and Fundamentals Analysis for FOCALIN XR

Last updated: February 20, 2026

What is FOCALIN XR and its Market Position?

FOCALIN XR (dexmethylphenidate hydrochloride extended-release), marketed by Novartis, is a prescription medication used primarily for Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults. As a methylphenidate derivative, it is part of the stimulant class within ADHD therapeutics.

The drug’s differentiated formulation provides a controlled, extended-release profile, reducing dosing frequency and enhancing compliance. FOCALIN XR’s global market share is significant in the ADHD segment, estimated at approximately 10% of the total ADHD prescription market, valued around $10 billion (IQVIA, 2022). Its competitive landscape involves brands like Concerta, Vyvanse, and Adderall.

What Are the Key Market Dynamics?

Market Size and Growth

The global ADHD market in 2022 was estimated at $10 billion, with a projected compound annual growth rate (CAGR) of 4% through 2027. Increasing awareness, diagnosis rates, and expanded adult ADHD treatment drive growth.

Key Therapeutic Competitors

• Concerta (Janssen)
• Vyvanse (Eli Lilly)
• Adderall (Teva, Teva variants)

FOCALIN XR’s market penetration benefits from its once-daily dosing and favorable side effect profile compared to immediate-release formulations.

Regulatory Environment and Approvals

Most countries classify dexmethylphenidate as a Schedule II controlled substance, requiring strict regulatory compliance. Regulatory authorities emphasize abuse deterrent formulations. FOCALIN XR’s patent portfolio has expired in several jurisdictions, creating vulnerability to generics.

Patent Status and Generics Competitor Threat

Since 2018, Novartis faced patent expiration challenges, enabling generic dexmethylphenidate formulations. In the U.S., generic competitors entered in 2019, causing price erosion [1].

What Are the Financial Fundamentals?

Revenue Trends

Novartis’ U.S. ADHD franchise, including FOCALIN XR, historically generated approximately $200 million annually, representing around 5% of Novartis’s specialty medicines revenue. Post-generic entry, revenue declined by an estimated 30% in 2020.

R&D and Patent Strategies

Novartis has invested in developing new formulations and delivery systems, including sustained release and abuse-deterrent formulations, targeting continued revenues beyond patent expiry.

Pricing and Reimbursement

Reimbursement for FOCALIN XR varies across regions. U.S. prices ranged from $250 to $300 for a 30-day supply; discounts and insurance negotiations significantly influence net pricing.

Manufacturing and Supply Chain Considerations

Supply chain stability is critical, especially amid global disruptions. FOCALIN XR’s manufacturing predominantly occurs in the U.S. and Europe, benefiting from established supply chains but vulnerable to raw material shortages.

How Do Regulatory and Patent Risks Affect Investment?

Patent cliffs in 2018-2019 resulted in revenue decline, prompting Novartis to explore new formulations and extended indications. Pending patent litigation and potential generics threaten future revenue streams.

An important aspect is Novartis’s strategy to defend its market share via product differentiation and pipeline development, including transdermal patches and novel delivery devices.

What Is the Outlook for Investment?

Positives

• Growing ADHD prevalence globally.
• High unmet need in adult ADHD, expanding market base.
• Continued innovation in formulations and delivery methods.

Risks

• Patent expiry leading to price erosion and market share decline.
• Regulatory hurdles for abuse-deterrent and generic formulations.
• Competitive pressure from generics and other branded drugs.

Critical Metrics

Metric	2021 Data	Notes
Global ADHD market size	~$10 billion	Growing at CAGR 4%
Novartis FOCALIN XR U.S. revenue	~$200 million pre-generic entry	Declined ~30% post-2019 due to generics
Patent expiration year	2018-2019	Led to increased generic competition
Number of generic entrants	Several since 2019	Price competition intensifies

Key Takeaways

• FOCALIN XR remains a relevant drug within ADHD treatment, especially among targeted patient groups.
• Patent expiry led to revenue decline, but innovation in formulations persists.
• Market growth driven by broader ADHD diagnosis and adult treatment, but competitive intensity increases.
• Investment hinges upon Novartis’s pipeline of new formulations, market share retention strategies, and regulatory landscape management.

FAQs

Q1: How much revenue does FOCALIN XR generate for Novartis?
Approximately $200 million annually before generic competition, declining since 2019.

Q2: What is the main competitive threat to FOCALIN XR?
Generic formulations of dexmethylphenidate entered the U.S. market in 2019, causing pricing erosion.

Q3: Are there ongoing patent protections or litigation initiatives?
Most patents expired by 2019, but litigation continues in some jurisdictions to delay generic entry.

Q4: What are Novartis’s strategies to sustain FOCALIN XR sales?
Developing new formulations, abuse-deterrent features, and expanding into adult ADHD treatment.

Q5: How does the regulatory environment impact FOCALIN XR?
Strict controls on controlled substances pose hurdles for market access and generic development.

References

[1] IQVIA. (2022). Global ADHD market report. IQVIA Insights.

[2] U.S. Food and Drug Administration. (2018). ANDA filings for dexmethylphenidate. FDA.

[3] Novartis AG. (2020). Annual Report. Novartis.